Study protocol

Can an App Supporting Psoriasis Patients Improve Adherence to Topical Treatment? A single-blind randomized controlled trial

Additional file 7: Guidelines for publication

The sponsor will no later than 90 days after the conclusion of the study inform the Danish Health Authority and the Committee on Health Research Ethics that the study has ended. For the Danish Health Authority, the EudraCT "End of Trial" form is to be used. For the Committee on Health Research Ethics, the “Form for reporting the end of study” is to be used and submitted electronically with the use of a digital signature.

No later than one year thereafter, the results of the study will be entered into EudraCT. The data will thereafter be made public at www.clinicaltrialsregister.eu. The study will also be made public at www.clinicaltrials.gov.

The Danish Health Authority and the Committee on Health Research Ethics may, if they deem it necessary, request the full report.

An attempt will be made to publish the results of the study in a peer-reviewed scientific dermatological journal with the corresponding author and co-authors of this protocol and with the invitation of the following list of co-authors:

Anton Pottegård[1], Helle Johannessen[2], Sören Möller[3], Benjamin August[4], and Steven R. Feldman[5]

1) Clinical Pharmacology, Department of Public Health, University of Southern Denmark, DK-5000 Odense C, Denmark, 2) Research Unit of User Perspectives, Department of Public Health, University of Southern Denmark, DK-5000 Odense C, Denmark, 3) Odense Patient data Explorative Network (OPEN), Odense University Hospital, Odense, Denmark & Department of Clinical Research, University of Southern Denmark, Odense, Denmark, 4) LEO® Pharma, 55 Industriparken, DK- 2750 Ballerup, Denmark, and 5) Wake Forest Baptist Medical Center, Winston-Salem, North Carolina, USA.

Any submitted manuscript will be accompanied by a note that Benjamin August may have a conflict of interest due to his employment relationship with LEO®, that Klaus Ejner Andersen has received sponsor support from LEO® for the study, and that some of Mathias Tiedemann Svendsen's salary has been paid throughout the study period by support from LEO®.

There are no provisions with respect to publication strategies in which all responsibility is delegated to the investigator.